Results 171 to 180 of about 10,848 (199)

Preliminary safety and efficacy of boven (Zanubrutinib, Obinutuzumab, and Venetoclax) as frontline therapy for older patients with Mantle Cell Lymphoma

Blood
Background: Frontline mantle cell lymphoma (MCL) treatments are rapidly evolving with incorporation of targeted therapies. We previously demonstrated the safety and efficacy of the BOVen triplet (Zanubrutinib, Obinutuzumab, and Venetoclax) in high ...
Anita Kumar, J. Soumerai, Reem Karmali, J. Abramson, Jeffrey A. Barnes, Bernadette Beatty, Jason Brecher, P. Caron, K. Carson, Maria Chabowska, Madelyn E. Coogan, J. Coyle, Kevin A. David, Meemanage D. De Zoysa, A. Doğan, Z. Epstein-Peterson, P. Ghione, Cameron Gordan, Leo I. Gordon, J. Haydu, Ephraim P. Hochberg, P. Johnson, A. Joseph, Akshata Kakolu, Alyssa Labarre, Carissa Laudati, J. Lue, Shuo Ma, R. Martignetti, C. Owens, O. Maas, Joanna Mi, Rachel Nazzaro, James O'Grady, Jessica Pendleton, G. Salles, V. Seshan, N. Slupe, P. Torka, A. Zelenetz   +39 more
semanticscholar   +1 more source

Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)

Blood
Background With the advent of effective targeted therapy, there is growing interest in chemotherapy-free regimens in patients (pts) with mantle cell lymphoma (MCL). Triplet combinations of the BTK inhibitors ibrutinib or zanubrutinib, venetoclax (V)
A. Kim, P. Riedell, C. Ryan, R. Redd, Clare Phinney, Juniper Mai, S. Pazienza, Caitlin Bravo, V. Kats, Salah Abdulkarim, Susan M Waisgerber, R. Merryman, David C. Fisher, Inhye E. Ahn, J. Crombie, O. Odejide, Ann S. LaCasce, C. Jacobson, E. Jacobsen, E. Parry, D. Qualls, A. Bessnow, M. Davids, Jennifer R. Brown, Jon E. Arnason, Michael Leukam, P. Armand, J. Kline, M. Murakami   +28 more
semanticscholar   +1 more source

Obinutuzumab

Reactions Weekly, 2021
  +4 more sources

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

Blood
Introduction: Combined therapy with covalent BTK inhibitors (BTKi) and BCL2 inhibitor +/- CD20 mAb leads to high rates of undetectable MRD (U-MRD) remission in patients (pts) with CLL (Jain, NEJM 2019; Munir NEJM 2023/2025; Wierda, JCO 2021; Kater,
Nitin Jain, A. Ferrajoli, M. Swaminathan, J. Burger, Vanthana Bharathi, Wei-Ying Jen, Himachandana Atluri, A. Bataller, E. Jabbour, T. Kadia, G. Borthakur, Koichi Takahashi, K. Chien, M. Yilmaz, N. Pemmaraju, N. Daver, F. Haddad, Y. Alvarado-Valero, J. Ishizawa, G. Montalban-Bravo, Cameron Noorbakhsh, Dhruv Kumar, Naveen Garg, H. Hwang, Wei Qiao, Cameron Garcia, Anna Evangelio, A. Ayala, G. Garcia-Manero, Deepa Sampath, Varsha Gandhi, Michael J. Keating, H. Kantarjian, W. Wierda   +33 more
semanticscholar   +1 more source

Obinutuzumab in systemic lupus erythematosus: a real-world experience

Frontiers in Immunology
Objectives To describe the real-world efficacy and safety of obinutuzumab in a heterogeneous systemic lupus erythematosus (SLE) population, including severe or refractory manifestations.
Chun-Mei Wu, Yinglu Wang, Sheng Chen, Yan-Wei Lin, F. Du, Xiao-Dong Wang, Sheng Chen, Liangjing Lu, Shuang Ye, Hui-Hua Ding, Qiong Fu   +10 more
semanticscholar   +1 more source

MRD-guided therapy of sonrotoclax (BGB-11417) + obinutuzumab (O) in patients with treatment-naive CLL: Initial results from an ongoing phase 1/1b study, BGB-11417-101

Blood
Introduction: The first-generation BCL2 inhibitor,venetoclax, is an effective treatment for CLL/SLL, but its usage may be limited by toxicity. Sonrotoclax, a next-generation BCL2 inhibitor, is a more selective and pharmacologically potent inhibitor
Marc S. Hoffmann, Shuo Ma, H. Eradat, Constantine S. Tam, M. Lasica, Paul J. Hampel, E. Verner, Lori Leslie, Christopher R. D'Angelo, J. Soumerai, M. Shadman, C. Cheah, Monica Tani, Yi-Qian Fang, Binghao Wu, G. Man, Sheel Patel, R. Vezan, Stephen Samuel Opat   +18 more
semanticscholar   +1 more source

Successful treatment of pemphigus vulgaris with obinutuzumab.

British Journal of Dermatology
This letter highlights the successful use of obinutuzumab as an alternative therapy for a patient with pemphigus vulgaris who could not tolerate rituximab.
Colin R Tang-Whitmore, Laureb Ostlund, K. Munson, B. Schultz   +3 more
semanticscholar   +1 more source

Obinutuzumab

Reactions Weekly, 2016
openaire   +2 more sources

Obinutuzumab

Drugs of the Future, 2011
null Karlin, L., null Salles, G.
openaire   +1 more source

Obinutuzumab

Reactions Weekly, 2019
  +4 more sources